Pharsight

Drugs that contain Ticagrelor

1. Brilinta patents expiration

BRILINTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6251910 ASTRAZENECA 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Jul, 2018

(5 years ago)

US6525060 ASTRAZENECA Triazolo(4,5-d)pyrimidine compounds
Dec, 2019

(4 years ago)

US7250419 ASTRAZENECA Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Dec, 2019

(4 years ago)

US7265124 ASTRAZENECA Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
Jul, 2021

(2 years ago)

USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(1 year, 9 days from now)

US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(5 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(6 years from now)

US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jan, 2036

(11 years from now)

US10300065

(Pediatric)

ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-848) Nov 05, 2023
M(M-283) May 09, 2025
Pediatric Exclusivity(PED) Nov 09, 2025
New Indication(I-851) May 28, 2023
New Strength(NS) Sep 03, 2018
New Indication(I-714) Sep 03, 2018
New Chemical Entity Exclusivity(NCE) Jul 20, 2016

NCE-1 date: 09 November, 2024

Market Authorisation Date: 03 September, 2015

Treatment: Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagre...

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents